Post-earnings recap
Reported
Thu, Aug 5, 2021
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
25%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
BridgeBio Pharma's earnings report shows a positive surprise in EPS, which contributed to a 6.25% increase in stock price. Investors reacted favorably to the management's comments about progress in their pipeline, despite the lack of revenue data. The absence of guidance may leave some investors cautious moving forward.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | -$0.66 | N/A | +28.80% |
| Revenue | N/A | N/A | N/A |
Management expressed satisfaction with the quarter's progress despite not providing specific revenue figures. They emphasized their commitment to pipeline development.
We are pleased with our progress in the quarter.
Our focus remains on advancing our pipeline.